0
Episode1113 of 1969
Længde24M
SprogEngelsk
FormatKategori
Two pharmaceutical companies, Eisai and Biogen, have published the results of an 18-month human trial for their new drug, lecanemab. It's meant to treat people with early stages of Alzheimer's disease, a devastating condition that causes the majority of dementia cases and affects hundreds of thousands of Canadians.
The results of the lecanemab trial are promising — the condition of people who were given the drug declined at a rate that was 27 per cent slower than those who were given a placebo. It's a glimmer of hope for those facing Alzheimer's disease, but questions about the new drug remain.
Today, Mike Crawley, a reporter with CBC's health unit, is here to explain how the drug works and what it may mean for people living with Alzheimer's disease.
Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis
Lyt og læs så meget du har lyst til
Opdag et kæmpe bibliotek fyldt med fortællinger
Eksklusive titler + Mofibo Originals
Opsig når som helst
Om Mofibo
Jobs
nye app-funktioner
Investor Relations
Presse
Bæredygtighed
Tilgængelighedserklæring
Whistleblow
Søg
Bøger
Bogserier
Mofibo Originals
Podcasts
Forfattere
Indlæsere
Kategorier
Hjælpecenter
Abonnementer
Køb gavekort
Indløs gavekort
Indløs kampagnekode
Studierabat
Dansk
Danmark
Privatlivspolitik
Medlemsvilkår
Cookies
